Background: The pharmaceutical industry began to rely heavily on new product development looking for achieving an excellent NPL process. That’s why, pharmaceutical marketing started to emphasize the pre-launch phase for the pharmaceutical products and began to apply many strategies, tactics, and activities to ensure launch readiness and successful market understanding and acceptance. Existing literature that elicit s theoretical and empirical evidence regarding the pre-launch phase and its impact on the launch readiness is li mited. Purpose: This research aims to identify the key success factors that impact the excellence of the new product launch process in the pharmaceutical industry. Methodology: A theoretical framework was developed from existing relevant literature then tested and empirical research was conducted using qualitative analysis technique via interviews with experts from the pharma ceutical field to get their insights. Findings: The findings indicate that there are 7 factors that are impacting the excellence of the NPL process. These fac tors are cross-functional collaboration, market analysis, pre-launch medical activities, pricing strategies, early access programs, human resources allocation and supply chain management strategies. In addition to that the excellence measures have been stratified into qualitative measure s , like customer acceptance and gaining high advocacy level of KOLs, and quantitative measures that repre sent the financial success of the drug in terms of rapid market penetration , gaining MS and the magnitude of MS gain. Limitations: The sample size was small and such a small sample size directed the sampling technique to be purposive sampling which may impact the representation of the total population. Moreover, the empirical data were influenced by the existing factors supposed by literature. Practical Implications: Planning and emphasizing on pre launch phase is crucial for the excellence of NPL. Moreover, considering the 7 mentioned factors is important for ensuring the qualitative and quantitative success of the new product introduction to the market.
Amsbaugh, P., & Pitta, D. A. (2006). New Product Introduction at TyRx Pharma, Inc. Journal of Product & Brand Management, 15, 468-472. https://doi.org/10.1108/10610420610712865
Atuahene-Gima, K. (2003). Adoption of New Products by the Sales Force: The Construct, Research Propositions, and Managerial Implications. Journal of Product Innovation Management, 14, 498-514. https://doi.org/10.1111/1540-5885.1460498
Balasubramanian, G. et al. (2016). An Overview of Compassionate Use Programs in the European Union Member States. Intractable and Rare Diseases Search, 5, 244-254.
Bates, A. K. (2008). Implementing a Pre-Launch Named Patient Programme: Evidence of Increased Market Share. Journal of Medical Marketing, 8, 319-324. https://doi.org/10.1057/jmm.2008.25
Berndt, E. et al. (2002). An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts. The Journal of Mental Health Policy and Economics, 5, 3-19.
Blau, G. E. et al. (2004). Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry. Journal of Product Innovation Management, 21, 227-245. https://doi.org/10.1111/j.0737-6782.2004.00075.x
Calantone, R. J., & Di Benedetto, C. A. (2007). Clustering Product Launches by Price and Launch Strategy. Journal of Business & Industrial Marketing, 22, 4-19. https://doi.org/10.1108/08858620710722789
Calantone, R., & Di Benedetto, C. A., (1988). An Integrative Model of the New Product Development Process: An Empirical Evidence. Journal of Product Innovation Management, 5, 201-215. https://doi.org/10.1111/1540-5885.530201
Chiesa, V. and Frattini, F. (2011). Commercializing Technological Innovation: Learning from Failures in High-Tech Markets. Journal of Product Innovation Management, 28, 437-454. https://doi.org/10.1111/j.1540-5885.2011.00818.x
Chin, J. (2007). Measuring Performance of Field-Medical Programmes: Medical Science Liaison Metrics Consensus. Journal of Commercial Biotechnology, 13, 177-182.
Danzon, P. M. et al. (2005). The Impact of Price Regulation on the Launch Delay of New Drugs—Evidence from Twenty-Five Major Markets in the1990s. Health Economics, 14, 269-292. https://doi.org/10.1002/hec.931
De Brentani, U. et al. (2010). Success in Global New Product Development: Impact of Strategy and the Behavioral Environment of the Firm. Journal of Product Innovation Management, 27, 143-160. https://doi.org/10.1111/j.1540-5885.2010.00707.x
Di Benedetto, C. A. (1999). Identifying the Key Success Factors in New Product Launch. Journal of Product Innovation Management, 16, 530-544. https://doi.org/10.1111/1540-5885.1660530
Dimasi, J. A., & Grabowski, H. G. (2007). The Cost of Biopharmaceutical R & D: Is Biotech Different? Managerial and Decision Economics, 28, 469-479. https://doi.org/10.1002/mde.1360
European Federation of Pharmaceutical Industries and Associations (2018). The Pharmaceutical Industry in Figures: Key Data 2018. EFPIA.
Evens, R. P., & Sylvestri, M. (2007). Product Launch and the Strategies, Processes, and Operations of Medical Affairs to Support Start-Up Companies. Drug Information Journal, 41, 743-759.
Greene, J. A. (2007). Pharmaceutical Marketing Research and the Prescribing Physician. Annals of Internal Medicine, 146, 742-748. https://doi.org/10.7326/0003-4819-146-10-200705150-00008
Griffin, A. (1997). PDMA Research on New Product Development Practices: Updating Trends and Benchmarking Best Practices. Journal of Product Innovation Management, 14, 429-458. https://doi.org/10.1111/1540-5885.1460429
Gupta, S. K., & Nayak, R. P. (2013). An Insight into the Emerging Role of Regional Medical Advisor in the Pharmaceutical Industry. Perspectives in Clinical Research, 4, 186-190. https://doi.org/10.4103/2229-3485.115386
Henard, D. H., & Szymanski, D. M. (2001). Customer Satisfaction: A Meta-Analysis of the Empirical Evidence. Journal of the Academy of Marketing Science, 29, 16-35.
Kohli, A. & Jaworski, B. (1990). Market Orientation: The Construct, Research Propositions, and Managerial Implications. Journal of Marketing, 54, 1-18. https://doi.org/10.1177/002224299005400201
Kuester, S. et al. (2012). Externally Directed and Internally Directed Market Launch Management: The Role of Organizational Factors in Influencing New Product Success. Journal of Product Innovation Management, 29, 38-52. https://doi.org/10.1111/j.1540-5885.2012.00968.x
Langerak, F. et al. (2004). The Impact of Market Orientation, Product Advantage, and Launch Proficiency on New Product Performance and Organizational Performance. Journal of Product Innovation Management, 21, 79-94. https://doi.org/10.1111/j.0737-6782.2004.00059.x
Lehtimaki, T. (2012). Managing the New Product Launch Process: Cross-Functional Information Exchange Perspective. International Journal of Advances in Management and Economics, 1, 31-41. https://doi.org/10.31270/ijame/01/04/2012/06
Matikainen, M. et al. (2015). Determinants of New Product Launch Success in the Pharmaceutical Industry. Journal of Pharmaceutical Innovation, 10, 175-189. https://doi.org/10.1007/s12247-015-9216-7
Montoya-Weiss, M., & Calantone, R. (1994). Determinants of New Product Performance: A Review and Meta-Analysis. Journal of Product Innovation Management, 11, 397-417. https://doi.org/10.1111/1540-5885.1150397
Nell, G. K. H. (2018). Medical Affairs. In D. Vohora, & G. Singh (Eds.), Pharmaceutical Medicine and Translational Clinical Research (pp. 393-399). Academic Press. https://doi.org/10.1016/B978-0-12-802103-3.00026-2
Paladino, A. (2007). Investigating the Drivers of Innovation and New Product Success: A Comparison of Strategic Orientations. Journal of Product Innovation Management, 24, 534-553. https://doi.org/10.1111/j.1540-5885.2007.00270.x
Palinkas, L. A. et al. (2015). Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Administration and Policy in Mental Health and Mental Health Services Research, 42, 533-544. https://doi.org/10.1007/s10488-013-0528-y
Patil, S. (2016). Early Access Programs: Benefits, Challenges, and Key Considerations for Successful Implementation. Perspectives in Clinical Research, 7, 4-8. https://doi.org/10.4103/2229-3485.173779
Rochford, L., & Wotruba, T. R. (1996). The Impact of Sales Management Changes on New Product Success. Journal of the Academy of Marketing Science, 24, Article No. 263. https://doi.org/10.1177/0092070396243007
Sandberg, B., & Aarikka-Stenroos, L. (2014). What Makes It So Difficult? A Systematic Review on Barriers to Radical Innovation. Industrial Marketing Management, 43, 1293-1305. https://doi.org/10.1016/j.indmarman.2014.08.003
Saunders, M., Lewis, P., & Thornhil, A. (2009). Analysing Qualitative Data. In M. Saunders, P. Lewis, & A. Thornhil (Eds.), Research Methods for Business Students (pp. 480-525). Pearson Education.
Setia, S. et al. (2018). Evolving Role of Pharmaceutical Physicians in Medical Evidence and Education. Advances in Medical Education and Practice, 9, 777-790. https://doi.org/10.2147/AMEP.S175683
Sisodia, S. (2014). A Review of New Drug Innovation—Emerging Challenges and Mitigation Strategies. IOSR Journal of Pharmacy, 4, 43-48.
Stremersch, S., & Van Dyck, W. (2009). Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field. Journal of Marketing, 73, 4-30. https://doi.org/10.1509/jmkg.73.4.004
Stros, M., & Lee, N. (2015). Marketing Dimensions in the Prescription Pharmaceutical Industry: A Systematic Literature Review. Journal of Strategic Marketing, 23, 318-336. https://doi.org/10.1080/0965254X.2014.931878
Terblanch, N. S. (2008). New Pharmaceutical Product Development: Barriers to Overcome and Opportunities to Exploit. Journal of Commercial Biotechnology, 14, 201-212.
Trim, P., & Pan, H. (2005). A New Product Launch Strategy (NPLS) Model for Pharmaceutical Companies. European Business Review, 17, 325-339. https://doi.org/10.1108/09555340510607370
Tyson, G. et al. (2010). Preparing the Market for a New Drug with an Effective “Medical Affairs Launch”. Pharmaceutical Commerce. https://www.pharmaceuticalcommerce.com/view/preparing-the-market-for- a-new-drug-with-an-effective-medical-affairs-launch
Verniers, I. et al. (2011). The Global Entry of New Pharmaceuticals: A Joint Investigation of Launch Window and Price. International Journal of Research in Marketing, 28, 295-308. https://doi.org/10.1016/j.ijresmar.2011.05.008
Wagner, J., & McCarthy, E. (2004). International Differences in Drug Prices. Annual Review of Public Health, 25, 475-495. https://doi.org/10.1146/annurev.publhealth.25.101802.123042